Brief Title
Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib
Official Title
Chart Review on Patients With Unresectable/Metastatic Cholangiocarcinoma Treated in the UNM Cancer Center With a Combination of Irinotecan, Capecitabine and Celecoxib
Brief Summary
Chart Review on Patients with unresectable/metastatic cholangiocarcinoma treated in the UNM Cancer Center with a combination of irinotecan, capecitabine and celecoxib.
Detailed Description
As above.
Study Type
Observational
Condition
Cholangiocarcinoma
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Estimated Enrollment
10
Start Date
November 2005
Completion Date
October 2006
Primary Completion Date
August 2006
Eligibility Criteria
Inclusion Criteria: - Patients with unresectable/metastatic cholangiocarcinoma treated in the UNM Cancer Center with a combination of irinotecan, capecitabine and celecoxib. Exclusion Criteria: - Not specified.
Gender
All
Ages
N/A - N/A
Accepts Healthy Volunteers
No
Contacts
Fa-Chyi Lee, MD, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT00320918
Organization ID
4504C
Study Sponsor
University of New Mexico
Study Sponsor
Fa-Chyi Lee, MD, Principal Investigator, University of New Mexico
Verification Date
December 2007